Welcome to our dedicated page for Lineage Cell Therapeutics SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lineage Cell Therapeutics, Inc. filings document the disclosures of a clinical-stage biotechnology company developing allogeneic cell therapies and cell transplant product candidates. The company’s reports and current-event filings cover financial results, business updates, pipeline developments, research collaborations, clinical-program milestones, and manufacturing progress involving programs such as OpRegen, OPC1, and ReSonance.
Regulatory filings also describe Lineage’s capital structure and financing activity, including common share offerings under shelf registration and at-the-market arrangements. Proxy materials cover board matters, executive compensation, equity awards, shareholder voting items, and governance disclosures, while 8-K filings record material events tied to collaborations, grant-related developments, operating results, and other corporate updates.
Lineage Cell Therapeutics reported second quarter 2026 results with total revenue of $1.1 million, down from $2.8 million a year earlier, mainly due to lower collaboration revenue under the Roche agreement and the prior termination of a VAC platform collaboration. Total operating expenses fell to $10.0 million from $22.5 million, reflecting the absence of a prior-year $14.8 million non-cash impairment charge. Loss from operations narrowed to $8.9 million from $19.8 million. Other income was $10.5 million versus other expense of $10.6 million, driven primarily by non-cash fair value remeasurement of warrant liabilities. Net income attributable to Lineage was $1.5 million, or $0.01 basic EPS, compared to a $30.5 million net loss in 2025.
Cash, cash equivalents and marketable securities totaled $50.8 million as of June 30, 2026, which the company expects will support planned operations into the third quarter of 2028. Operationally, Lineage highlighted positive three-year OpRegen data in geographic atrophy, advancement of COR1 for corneal endothelial disease into in‑vivo animal testing in 2026, ongoing OPC1 DOSED study enrollment, continued ILT1 manufacturing scale-up, preclinical progress in the ReSonance (ANP1) hearing loss program under a WDI collaboration, and the establishment of a Scientific Advisory Board.
BlackRock, Inc. reports beneficial ownership of common stock of Lineage Cell Therapeutics Inc. BlackRock and certain of its business units beneficially own 13,185,489 shares of Lineage common stock, representing 5.3% of the class.
BlackRock has sole voting power over 13,024,110 shares and sole dispositive power over 13,185,489 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Lineage’s outstanding common shares.
Lineage Cell Therapeutics director and 10% owner Neal C. Bradsher reported a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. They were granted on July 1, 2026 as director compensation under Lineage’s 2021 Equity Incentive Plan.
According to the filing, these options will vest and become exercisable on the earlier of July 1, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. The report also lists several existing option holdings with exercise prices between $0.8263 and $2.86 per share, expiring from 2029 through 2035.
Lineage Cell Therapeutics director Anula Jayasuriya received a stock option grant covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.
The option will vest and become exercisable on the earlier of July 1, 2027 and the company’s next annual meeting of shareholders, subject to Jayasuriya’s continuous service with the company. Following this grant, the filing shows 125,000 derivative securities held directly.
Lineage Cell Therapeutics director Michael H. Mulroy received a grant of stock options representing 125,000 common shares. The options carry an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase or sale.
The options will vest and become exercisable on the earlier of July 1, 2027 or the date of the company’s next annual shareholder meeting, subject to his continuous service with the company.
Lineage Cell Therapeutics director Deborah J. Andrews received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.3000 per share and expire on July 1, 2036. They were awarded as a compensation-related grant rather than an open-market purchase or sale.
According to the terms, the options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics' next annual meeting of shareholders, provided Andrews continues to serve the company through that time. Following this grant, she holds stock options for 125,000 shares directly.
Lineage Cell Therapeutics director Russell Angus received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036.
According to the footnote, the options will vest and become exercisable on the earlier of July 1, 2027 and the date of Lineage Cell Therapeutics’ next annual meeting of shareholders, in each case only if he continues to serve with the company. After this grant, his reported derivative holdings from this award total 125,000 options.
Lineage Cell Therapeutics director Dipti Amin received a stock option grant covering 125,000 common shares. The option has an exercise price of $1.30 per share and expires on July 1, 2036. It will vest and become exercisable on the earlier of July 1, 2027 and the date of the company’s next annual shareholder meeting, subject to Amin’s continuous service. Following this grant, Amin holds options for 125,000 shares directly.
Lineage Cell Therapeutics held its annual shareholder meeting, where investors elected seven directors to serve until the 2027 meeting. Each nominee, including CEO Brian M. Culley and Chair Angus C. Russell, received over 89.9 million votes in favor, with sizable broker non-votes.
Shareholders also ratified Baker Tilly US, LLP as independent auditor for the 2026 fiscal year and approved, on an advisory basis, the compensation program for named executive officers. Separately, Lineage withdrew its application for a CIRM CLIN2 grant for OPC1 but stated that this withdrawal does not affect its current or planned development of OPC1 in the ongoing DOSED spinal cord injury study.